We have heard much hullabaloo about adoptive T cell therapy approaches with tumour infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cell therapies, but what about T cell receptor (TCR) therapy?
Over the last couple of years, various experts we have interviewed have alluded to TCR approaches in the pipeline that they have been involved in or come across, but this is not a topic we have covered in-depth as we, like many other observers, have been on the sidelines waiting for solid clinical data to mature.
That time finally came around at ASCO last month, where we had the opportunity to discuss an NY-ESO–1 based TCR with one of the companies in this space, namely Adaptimmune.
We also covered several other constructs they have in their pipeline.
Inevitably there have been quite a few R&D setbacks with some of the TCR approaches evaluated, going back to Dr Steven Rosenberg and the NIH experiments back in the 1990’s with MART–1 as a target.
I was therefore really intrigued to find out more about how are Adaptimmune faring, what technical and clinical challenges remain, where are the programs going, and what have we learned so far?